薬理と治療

Abstract

Objective We aimed to clarify the effect of a nutritional supplement containing chondroitin sulfate oligosaccharides (CSOS) on blood pressure reduction and blood vessels in healthy adults with a tendency toward hypertension. Methods We conducted a randomized, double–blind, placebo–controlled, parallel–group study on participants aged 40 to under 70, and with high blood pressure (130 mmHg < systolic blood pressure [SBP] < 140 mmHg and diastolic blood pressure [DBP] < 90 mmHg). The participants were randomly assigned to receive either the test supplement or the placebo supplement, daily for 12 weeks. The daily dose of the test supplement contained 100 mg CSOS. We measured blood pressure as the primary outcome and CAVI (Cardio–Ankle Vascular Index) and FMD (Flow–Mediated Dilatation) as the secondary outcomes. Results 69 participants were eligible for efficacy analyses. There were no significant differences in blood pressure between the groups (estimated difference 1.00 mmHg, 95% CI –4.26 to 6.25, P = 0.71 in SBP; estimated difference –2.30 mmHg, 95% CI –5.91 to 1.30, P = 0.21 in DBP), and no significant changes were observed in CAVI (estimated difference –0.01, 95% CI –0.27 to 0.25, P = 0.93) and FMD (estimated difference –0.27, 95% CI –1.24 to 0.70, P = 0.58), either. However, the analyses on a subgroup of men with total cholesterol levels above 200 mg/dL showed significant decrease in DBP (estimated difference –7.74 mmHg, 95% CI –14.8 to –0.7, P = 0.034) and creatine kinase (estimated difference –46.69 U/L, 95% CI –80.67 to –12.71, P = 0.010) Conclusion The results of this study suggest that 12 weeks of continuous intake of CSOS may not affect blood pressure reduction and blood vessels (UMIN ID: UMIN000052732) Although, in men with total cholesterol levels exceeding 200 mg/dL, continuous intake of nutritional supplements containing CSOS for 12 weeks was shown to significantly reduce diastolic blood pressure and CK levels. Therefore, further detailed studies are necessary for these findings. (Jpn Pharmacol Ther 2025;53:959‒72)